WO2003047523A2 - Raf-mek-erk pathway inhibitors to treat cancer - Google Patents
Raf-mek-erk pathway inhibitors to treat cancer Download PDFInfo
- Publication number
- WO2003047523A2 WO2003047523A2 PCT/US2002/038402 US0238402W WO03047523A2 WO 2003047523 A2 WO2003047523 A2 WO 2003047523A2 US 0238402 W US0238402 W US 0238402W WO 03047523 A2 WO03047523 A2 WO 03047523A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- raf
- mek
- inhibitor
- imatinib
- erk pathway
- Prior art date
Links
- HICUGGYRYZOXJI-UHFFFAOYSA-N CCC1C=CCC1 Chemical compound CCC1C=CCC1 HICUGGYRYZOXJI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the invention described herein is in the field of cancer therapy, and preferably for the treatment of chronic myelogenous leukemia.
- CML chronic myelogenous leukemia
- GleevecTM also referred to as imatinib
- Imatinib treats CML by blocking Bcr-Abl kinase activity.
- the Abl kinase was chosen as a molecular target in the treatment against cancer since 95% of patients with CML have activation of the Abl pathway that occurs through chromossomal translocations that result in fusion of the Bcr and Abl genes.
- a key pathway that is up-regulated in CML cells that are resistant to imatinib is the RAF-MEK-ERK pathway. Therefore, treatment with inhibitors of the RAF-MEK-ERK pathway should lead to remissions in patients with imatinib resistant CML.
- the invention described herein presents methods and compositions for treating cancers that involve up-regulation of one or more molecules in the pathway: RAF-MEK- ERK.
- An obj ect of the invention is a description of inhibitors of the RAF-MEK-ERK pathway that are beneficially applied to the treatment of certain forms of cancer, preferably CML, and more preferably to those forms of CML that are resistant to Bcr- Abl kinase inhibitors, and most preferably to those forms of CML that are resistant to the Bcr-Abl kinase inhibitor, imatinib.
- Another object of the invention is a description of RAF inhibitors, preferably Bay
- Bcr-Abl kinase inhibitors preferably imatinib
- Still another object of the invention is a description of MEK inhibitors, preferably CI-1040, alone or in combination with Bcr-Abl kinase inhibitors, preferably imatinib, for the treatment of CML.
- Another object of the invention is a description of methods and compositions for formulating and administering inhibitors of the RAF-MEK-ERK pathway, preferably in combination with Bcr-Abl kinase inhibitors and more preferably with the Bcr-Abl kinase inhibitor, imatinib.
- Figure 1 shows the RAF-MEK-ERK pathway that becomes up-regulated in certain cancer cells, including chronic myelogenous leukemia. Also shown are the compounds BAY 43-9006, and CI-1040, and the proteins in the pathway that they affect, RAF and MEK, respectively.
- Figure 2 shows the structure of BAY 43-9006.
- Figure 3 shows the effects of the RAF kinase inliibitor, BAY 43-9006, and imatinib, on imatinib-resistant CML Cells.
- Figure 4 shows the effects of the RAF kinase inhibitor, BAY 43-9006, on imatinib-resistant CML Cells. The results are from 3 experiments.
- Figure 5 shows the effects of the RAF kinase inhibitor, BAY 43-9006, on ERK phosphorylation.
- Raf, MEK, or ERK are up-regulated
- compounds that inhibit the activities of these molecules will have beneficial effects for treating such cancers.
- An example of one such cancer, also shown in Figure 1, is chronic myelogenous leukemia.
- treating patients with non-toxic doses of, preferably, 200-400 mg and higher of the Raf kinase inhibitor BAY 43-9006 (Endocr. Relat. Cancer 8, 219 [2001]) will result in remissions, or
- PCT/US00/00648 as are numerous other RAF kinase inhibitors.
- the MEK inhibitor, CI-1040 is described in Oncogene 19, 6594 (2000).
- Imatinib, or Gleevec,TM is described in U.S. Patent 5, 521, 184.
- up-regulated or “up-regulation” of the RAF-MEK-ERK pathway is meant 0 elevated levels, by whatever molecular mechanism, of one or more of the proteins, RAF MEK, or ERK, or increases in their enzymatic activity, or changes in their normal substrate affinity when compared to normal cells. It will be appreciated that the compounds that affect RAF, MEK, or ERK may be used alone, or in combination. They may also be used in combination with other compounds known to affect particular cancers where the RAF-MEK-ERK pathway is up-regulated.
- the drug imatinib (GleevecTM) is used to treat CML patients; thus, imatinib resistance that develops in certain advanced staged CML patients that causes up-regulation of the RAF-MEK-ERK pathway can be treated with the appropriate compounds that control the up-regulation of the appropriate molecules in the RAF-MEK- ERK pathway.
- Such compounds can be combined with imatinib for treatment of a CML patient before imatinib resistance develops, or without imatinib after resistance has developed.
- the pathway in question and the sites of action of BAY 43-9006, CI-1040 and imatinib are illustrated in Figure 1.
- RAF-MEK- ERK pathway for the treatment of CML.
- cells from leukemia patients (Ph+) have elevated phospho-ERK levels at least in part due to elevated, or up-regulated, RAF kinase activity.
- imatinib treatment results in decreased phospho-ERK levels.
- the present invention also relates to pharmaceutical compositions for administration to humans that comprise an inhibitor of the RAF-MEK-ERK pathway alone, or in combination with imatinib.
- compositions for enteral administration such as nasal, buccal, rectal or, especially, oral, and parenteral administration, such as intravenous, intramuscular or subcutaneous.
- the compositions comprise the inhibitor on its own or, preferably, together with a pharmaceutically acceptable carrier.
- the dose of inhibitor depends on the disease to be treated, preferably CML, and more preferably imatinib resistant CML, and the age, weight and individual condition of a patient, and the mode of administration.
- the invention relates also to processes, and to the use of inhibitors of the RAF- MEK-ERK pathway in the preparation of pharmaceutical compositions alone, or in combination with imatinib.
- a pharmaceutical composition that is suitable for administration to a human suffering from a cancer that is responsive to inhibition of a protein tyrosine kinase.
- the cancer is CML, and more preferably it is imatinib resistant CML which composition comprises an inhibitor, or a salt thereof where salt-fonning groups are present, in an amount that is effective in inhibiting the protein tyrosine kinase, together with at least one pharmaceutically acceptable carrier.
- compositions for the prophylactic or, especially, therapeutic treatment of preferably CML, and more preferably imatinib- resistant CML which composition comprises as active ingredient an inhibitor, or a pharmaceutically acceptable salt thereof, in an amount that is prophylactically or, especially, therapeutically effective against the mentioned diseases.
- the pharmaceutical compositions comprise from approximately 1% to approximately 95% of the appropriate inhibitor, dosage forms that are in single dose form preferably comprising from approximately 20% to approximately 90% active ingredient, and dosage forms that are not in single dose form preferably comprising from approximately 5% to approximately 20% active ingredient.
- Unit dose forms are, for example, dragees, tablets, ampoules, vials, suppositories or capsules.
- compositions of the present invention are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes.
- solutions that can be used with the appropriate inhibitor including suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions, which, for example in the case of lyophilized compositions comprising the active ingredient on its own or together with a carrier, e.g. mannitol, may be prepared before use.
- compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers, and are prepared in a manner known per se, for example by means of conventional dissolving or lyophilising processes.
- the said solutions or suspensions may comprise viscosity-increasing substances, such as sodium carboxy-methylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin, or also solubilisers, for example .RTM.Tween 80 >polyoxyethylene(20) sorbitan monooleate; trademark of ICI Americas, Inc, USA.
- Synthetic or semi-synthetic oils as are know in the art may be used for injection of the appropriate inhibitor.
- Particularly useful can be liquid fatty acid esters which contain a long-chain fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms.
- Pharmaceutical compositions will preferably be used in oral form, and can be obtained, for example, by combining a RAF-MEK-ERK pathway inhibitor, with or without a Bcr-Abl tyrosine kinase inhibitor, with one or more solid carriers, granulating a resulting mixture, where appropriate, and processing the mixture or granules, if desired, where appropriate with the addition of additional excipients, to form tablets or dragee cores.
- Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and or calcium phosphates, for example tri-calcium phosphate or calcium hydrogen phosphate, and also binders, such as starches, for example corn, wheat, flee or potato starch, methylcellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches and also carboxymethyl starch, cross-linked polyvinylpyrrolidone, or alginic acid or a salt thereof, such as sodium alginate.
- fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and or calcium phosphates, for example tri-calcium phosphate or calcium hydrogen phosphate
- binders such as starches, for example corn
- Additional excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
- Pharmaceutical compositions for oral administration are also hard gelatin capsules, and soft sealed capsules consisting of gelatin and a plasticiser, such as glycerol or sorbitol.
- the hard gelatin capsules may comprise an appropriate inhibitor in the form of granules, for example in admixture with fillers, such as corn starch, binders and/or glidants, such as talc or magnesium stearate, and, where appropriate, stabilizers.
- the active ingredient is preferably dissolved or suspended in suitable liquid excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene glycol or propylene glycol, it likewise being possible to add stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type.
- suitable liquid excipients such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene glycol or propylene glycol, it likewise being possible to add stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type.
- oral dosage forms are, for example, syrups prepared in customary manner which comprise the appropriate inhibitor, for example, in suspended form and in a concentration of approximately from 5% to 20%, preferably approximately 10% or in a similar concentration that provides a suitable single dose when administered, for example, in a measure of 5 or 10 ml.
- suitable are, for example, powdered or liquid concentrates for the preparation of shakes, for example in milk. Such concentrates may also be packed in single dose quantities.
- aqueous solutions of an active ingredient in water-soluble form for example in the form of a water-soluble salt, or aqueous injection suspensions that comprise viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers.
- the active ingredient where appropriate together with excipients, can also be in the form of a lyophilisate and be made into a solution prior to parenteral administration by the addition of suitable solvents.
- the instant invention relates to a method for the treatment of the pathological conditions mentioned above, especially those which are responsive to inhibition of tyrosine protein kinases, preferably CML, and more preferably CML that is resistant to Bcr-Abl tyrosine kinase inhibitors.
- a RAF-MEK-ERK pathway inhibitor with or without a Bcr-Abl tyrosine kinase inhibitor, may be administered prophylactically or therapeutically as such, or in the form of a pharmaceutical composition.
- Ba/F3 mouse pre-B cells containing empty expression vector (Ba/F3) or stable expressing wildtype Bcr-Abl (P210 WT), or the imatinib resistant T315I or E255K mutants (P210 T315I, P210 E255K) were cultured in RPMI medium containing 10% serum.
- Cell proliferation assays were performed as follows. On dayl, 2xl0 5 cells were plated in 24 well plates with 1.2ml of media. The appropriate compound, at the chosen concentration was then added to the media in a final DMSO concentration of 0.2%. On day 3, the cells were resuspended, and 0.5 ml of the cell suspension was and diluted with PBS (1 :2). Finally, cell proliferation (cell viability) was measured by trypan blue dye exclusion using CEDEX system (Innovatis).
- Bcr-Abl were sensitive to imatinib. IC50s for inhibition by imatinib were 0.5 ⁇ M for the wild type expressing cells and over ten-fold higher for the three other cell lines. In contrast, as shown in Figure 4, the proliferation of all four cell lines was inhibited by BAY 43-9006, with IC50s ranging from 4-8 ⁇ M.
- the experiment was conducted as follows. On day 1, 2 x 10 6 cells were plated in a 6 well plate in medium containing 10% serum, and on day 2 the cells were treated with the relevant compound dissolved in DMSO. The final DMSO concentration was 0.2%. Next, the cells were spun down, and washed once with 2 ml of ice-cold phosphate buffered saline, and then lysed with 150ml buffer. Next, 50 ul of cell lysates was electorphoresed in 10% Tris-Glycine gels, followed by treatment with a 1° antibody which was a phospho-ERK polyclonal rabbit antibody used at 1 : 1000 dilution. It was obtained from Cell Signaling. The 1° was followed by a 2° antibody which was goat anti-rabbit horse radish peroxidase antibody, and it was used at a dilution of 1 : 1000.
- FIG. 5 shows the results. Only those Ba/F3 cells expressing wild type Bcr-Abl were sensitive to imatinib. In contrast, phospho-ERK levels in these cells, as well as Bcr-Abl kinase imatinib resistant domain mutants, E255K and T3151, also showed a decrease in phospho-ERK levels in the presence of BAY 43-9006.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002466762A CA2466762A1 (en) | 2001-12-04 | 2002-12-03 | Raf-mek-erk pathway inhibitors to treat cancer |
AU2002365899A AU2002365899B2 (en) | 2001-12-04 | 2002-12-03 | RAF-MEK-ERK pathway inhibitors to treat cancer |
EP02804478A EP1578346A4 (en) | 2001-12-04 | 2002-12-03 | Raf-mek-erk pathway inhibitors to treat cancer |
JP2003548784A JP2005526008A (en) | 2001-12-04 | 2002-12-03 | RAF-MEK-ERK pathway inhibitors for treating cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33688601P | 2001-12-04 | 2001-12-04 | |
US60/336,886 | 2001-12-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003047523A2 true WO2003047523A2 (en) | 2003-06-12 |
WO2003047523A3 WO2003047523A3 (en) | 2006-02-23 |
Family
ID=23318114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/038402 WO2003047523A2 (en) | 2001-12-04 | 2002-12-03 | Raf-mek-erk pathway inhibitors to treat cancer |
Country Status (6)
Country | Link |
---|---|
US (1) | US7307071B2 (en) |
EP (1) | EP1578346A4 (en) |
JP (1) | JP2005526008A (en) |
AU (1) | AU2002365899B2 (en) |
CA (1) | CA2466762A1 (en) |
WO (1) | WO2003047523A2 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009961A2 (en) * | 2003-07-23 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
WO2005019192A1 (en) * | 2003-07-30 | 2005-03-03 | Merck Patent Gmbh | Urea derivatives and their use as tyrosinkinase inhibitors |
WO2006026501A1 (en) * | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions for the treatment of cancer |
WO2007059155A1 (en) * | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Treatment of cancers having resistance to chemotherapeutic agents |
WO2007076092A2 (en) | 2005-12-23 | 2007-07-05 | Amgen Inc. | Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases |
WO2007089445A2 (en) | 2006-01-27 | 2007-08-09 | Amgen Inc. | Ang2 and vegf inhibitor combinations |
WO2008089388A2 (en) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
WO2007116029A3 (en) * | 2006-04-07 | 2008-12-11 | Novartis Ag | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor |
WO2008089389A3 (en) * | 2007-01-19 | 2009-01-08 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
US7678811B2 (en) | 2002-02-11 | 2010-03-16 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US7829560B2 (en) | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US7902192B2 (en) | 2003-05-15 | 2011-03-08 | Arqule, Inc. | Inhibitors of P38 and methods of using the same |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2012044577A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
US8178672B2 (en) | 2004-10-19 | 2012-05-15 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase |
WO2012162293A1 (en) * | 2011-05-23 | 2012-11-29 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
AU2013200394B2 (en) * | 2003-07-23 | 2015-07-09 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
US9308244B2 (en) | 2007-03-26 | 2016-04-12 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
US10500193B2 (en) | 2011-11-02 | 2019-12-10 | Synta Pharmaceuticals Corporation | Combination therapy of HSP90 inhibitors with platinum-containing agents |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US20060234931A1 (en) * | 2003-07-17 | 2006-10-19 | Biggs William H Iii | Treatment of diseases with kinase inhibitors |
EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
CA2560269A1 (en) * | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
EP2295426A1 (en) * | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
US7169864B2 (en) * | 2004-12-01 | 2007-01-30 | Novolen Technology Holdings, C.V. | Metallocene catalysts, their synthesis and their use for the polymerization of olefins |
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
US20060233705A1 (en) * | 2005-04-19 | 2006-10-19 | Schuller Hildegard M | Diagnosis by determination of hyperactivity or increased expression of members of cell signaling pathways |
CA2629863A1 (en) * | 2005-11-14 | 2007-05-24 | Scott Wilhelm | Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors |
ATE524177T1 (en) | 2006-03-30 | 2011-09-15 | Nerviano Medical Sciences Srl | USE OF A KINASE INHIBITOR TO TREAT CERTAIN RESISTANT TUMORS |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
AU2009322158A1 (en) * | 2008-12-05 | 2010-06-10 | Arqule, Inc. | RAF inhibitors and their uses |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
EP2688585B1 (en) | 2011-03-23 | 2018-09-05 | The Regents of The University of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
SG10201708494QA (en) | 2012-08-17 | 2017-11-29 | Hoffmann La Roche | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
EP3143166A4 (en) * | 2014-05-16 | 2018-04-18 | University of Massachusetts | Treating chronic myelogenous leukemia (cml) |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
CN112041307B (en) | 2018-02-06 | 2024-02-09 | 伊利诺伊大学评议会 | Substituted benzothiophene analogs as selective estrogen receptor degrading agents |
WO2020055359A2 (en) * | 2018-08-10 | 2020-03-19 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Oral dosage form of sorafenib tosylate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57122119A (en) * | 1981-01-22 | 1982-07-29 | Sanshin Ind Co Ltd | Port scavenging type 2 cycle internal combustion engine |
AT402431B (en) | 1988-11-24 | 1997-05-26 | Avl Verbrennungskraft Messtech | TWO-STROKE INTERNAL COMBUSTION ENGINE |
AU6910994A (en) * | 1993-05-14 | 1994-12-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity |
AU727939B2 (en) * | 1996-04-03 | 2001-01-04 | Merck & Co., Inc. | A method of treating cancer |
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
SE513446C2 (en) * | 1999-01-19 | 2000-09-11 | Electrolux Ab | Crankcase coil internal combustion engine of two stroke type |
JP2005502643A (en) * | 2001-08-10 | 2005-01-27 | ノバルティス アクチエンゲゼルシャフト | Use of C-SRC inhibitors alone or in combination with STI571 for leukemia treatment |
US20040065280A1 (en) * | 2002-10-04 | 2004-04-08 | Homelite Technologies Ltd. | Two-stroke engine transfer ports |
-
2002
- 2002-12-03 EP EP02804478A patent/EP1578346A4/en not_active Withdrawn
- 2002-12-03 WO PCT/US2002/038402 patent/WO2003047523A2/en not_active Application Discontinuation
- 2002-12-03 AU AU2002365899A patent/AU2002365899B2/en not_active Ceased
- 2002-12-03 US US10/308,721 patent/US7307071B2/en not_active Expired - Fee Related
- 2002-12-03 JP JP2003548784A patent/JP2005526008A/en active Pending
- 2002-12-03 CA CA002466762A patent/CA2466762A1/en not_active Abandoned
Non-Patent Citations (15)
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
US7678811B2 (en) | 2002-02-11 | 2010-03-16 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US8071616B2 (en) | 2002-02-11 | 2011-12-06 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7902192B2 (en) | 2003-05-15 | 2011-03-08 | Arqule, Inc. | Inhibitors of P38 and methods of using the same |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
WO2005009961A3 (en) * | 2003-07-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
AU2011201337B2 (en) * | 2003-07-23 | 2013-02-14 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
WO2005009961A2 (en) * | 2003-07-23 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
HRP20060073B1 (en) * | 2003-07-23 | 2014-03-14 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
NO335323B1 (en) * | 2003-07-23 | 2014-11-10 | Bayer Healthcare Llc | Fluoro-substituted omega-carboxyaryldiphenylurea compounds, their use for the manufacture of a medicament for the treatment and prophylaxis of diseases and conditions, and a pharmaceutical composition thereof. |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
EA010485B1 (en) * | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | N,n-diphenyl urea derivative, pharmaceutical composition (embodiments) thereof, and method for the treatment and prevention of diseases and conditions using it (embodiments) |
AU2004259760B2 (en) * | 2003-07-23 | 2010-12-23 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
AU2004259760B9 (en) * | 2003-07-23 | 2011-02-03 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
AU2013200394B2 (en) * | 2003-07-23 | 2015-07-09 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
CN1856469B (en) * | 2003-07-23 | 2013-03-06 | 拜耳医药保健有限责任公司 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
WO2005019192A1 (en) * | 2003-07-30 | 2005-03-03 | Merck Patent Gmbh | Urea derivatives and their use as tyrosinkinase inhibitors |
US7829560B2 (en) | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
US8114873B2 (en) | 2004-07-08 | 2012-02-14 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase |
JP2008511686A (en) * | 2004-08-27 | 2008-04-17 | バイエル、ファーマシューテイカルズ、コーポレイション | Novel pharmaceutical composition for the treatment of cancer |
WO2006026501A1 (en) * | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions for the treatment of cancer |
CN101048140B (en) * | 2004-08-27 | 2013-06-19 | 拜尔保健公司 | Novel pharmaceutical compositions for the treatment of cancer |
US8178672B2 (en) | 2004-10-19 | 2012-05-15 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
WO2007059155A1 (en) * | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Treatment of cancers having resistance to chemotherapeutic agents |
EP2481729A1 (en) | 2005-12-23 | 2012-08-01 | Amgen Inc. | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases |
WO2007076092A2 (en) | 2005-12-23 | 2007-07-05 | Amgen Inc. | Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases |
WO2007089445A2 (en) | 2006-01-27 | 2007-08-09 | Amgen Inc. | Ang2 and vegf inhibitor combinations |
EP2574340A3 (en) * | 2006-04-07 | 2013-04-17 | Novartis AG | Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor |
WO2007116029A3 (en) * | 2006-04-07 | 2008-12-11 | Novartis Ag | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor |
US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
WO2008089389A3 (en) * | 2007-01-19 | 2009-01-08 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
WO2008089388A3 (en) * | 2007-01-19 | 2008-12-31 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
WO2008089388A2 (en) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
US9308244B2 (en) | 2007-03-26 | 2016-04-12 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US20120015973A1 (en) * | 2008-12-10 | 2012-01-19 | Novartis Ag | Mek mutations conferring resistance to mek inhibitors |
US9084781B2 (en) * | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
US9279144B2 (en) | 2010-02-25 | 2016-03-08 | Dana-Farber Cancer Institute, Inc. | Screening method for BRAF inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US8637246B2 (en) | 2010-02-25 | 2014-01-28 | Dana-Farber Cancer Institute, Inc. | BRAF mutations conferring resistance to BRAF inhibitors |
EP3028699A1 (en) | 2010-02-25 | 2016-06-08 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
WO2012044577A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
WO2012162293A1 (en) * | 2011-05-23 | 2012-11-29 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
US10500193B2 (en) | 2011-11-02 | 2019-12-10 | Synta Pharmaceuticals Corporation | Combination therapy of HSP90 inhibitors with platinum-containing agents |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Also Published As
Publication number | Publication date |
---|---|
JP2005526008A (en) | 2005-09-02 |
AU2002365899A1 (en) | 2003-06-17 |
AU2002365899B2 (en) | 2007-09-13 |
US20030125359A1 (en) | 2003-07-03 |
EP1578346A4 (en) | 2007-11-28 |
CA2466762A1 (en) | 2003-06-12 |
WO2003047523A3 (en) | 2006-02-23 |
US7307071B2 (en) | 2007-12-11 |
EP1578346A2 (en) | 2005-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7307071B2 (en) | RAF-MEK-ERK pathway inhibitors to treat cancer | |
Zhao et al. | The clinical development of MEK inhibitors | |
US12011449B2 (en) | Therapeutic combinations comprising a c-RAF inhibitor | |
Ravnan et al. | Vemurafenib in patients with BRAF V600E mutation–positive advanced melanoma | |
Feleszko et al. | Lovastatin and tumor necrosis factor‐α exhibit potentiated antitumor effects against Ha‐ras‐transformed murine tumor Via inhibition of tumor‐induced angiogenesis | |
Vlahopoulos et al. | New use for old drugs? Prospective targets of chloroquines in cancer therapy | |
Nakamura et al. | PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas | |
US8629135B2 (en) | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer | |
JP3020277B2 (en) | Use of taxol to treat lymphoma and breast cancer | |
WO2021027912A1 (en) | Chidamide-containing anti-tumor pharmaceutical composition and use thereof | |
JP2020516689A (en) | Compounds, compositions and methods for treating or preventing acute lung injury | |
JP2020147598A (en) | Tyrosine kinase inhibitor used in cancer treatment in collaboration with reduced caloric intake | |
KANG et al. | In vitro evaluation of antiproliferative potential of calcium channel blockers in human Tenon's fibroblasts | |
KR102128866B1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
EP1575489A2 (en) | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | |
Luo et al. | Dual-functional MN-08 attenuated pulmonary arterial hypertension through vasodilation and inhibition of pulmonary arterial remodeling | |
Segatto et al. | Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer | |
CN109568313B (en) | Anti-tumor combined medicine and application thereof in preparing anti-cancer medicine | |
TWI501762B (en) | Novel use of adapalene in treating cancer | |
Li et al. | Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL | |
JP2023502252A (en) | Compounds, Compositions and Methods for Treating Ischemia-Reperfusion Injury and/or Lung Injury | |
JP7323457B2 (en) | Methods and pharmaceutical compositions for the treatment of mast cell disease | |
WO2006124544A2 (en) | Use of tyrosine kinase inhibitors in the treatment of metabolic disorders | |
WO2024088193A1 (en) | Combination of aurora a and parp inhibitors for treatment of cancers | |
CN115920062A (en) | Combined medicine and application thereof in preventing or treating liver cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2466762 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002365899 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003548784 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002804478 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 782/KOLNP/2004 Country of ref document: IN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2002804478 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002804478 Country of ref document: EP |